Sarepta to Present Duchenne Gene Therapy Data at Muscle Society Congress
Sarepta Therapeutics will present new data from its Duchenne muscular dystrophy portfolio at the World Muscle Society annual congress in Hiroshima. A late-breaking poster will detail efficacy and safety of delandistrogene moxeparvovec in older ambulatory patients. The presentations will occur from September 29 to October 3.
Sarepta Therapeutics is scheduled to showcase its Duchenne muscular dystrophy treatment portfolio at the World Muscle Society's 31st annual congress in Hiroshima, Japan, running from late September through early October. The company's presentation lineup includes a late-breaking poster focused on delandistrogene moxeparvovec, examining both efficacy and safety outcomes specifically in older patients who remain ambulatory.
This patient subgroup represents a key area of interest in Duchenne research, as clinical trials historically centered on younger, non-ambulatory populations. The company, which positions itself as a leader in precision genetic medicine for rare diseases, will use the international platform to share findings from its ongoing development program. The congress serves as a major venue for neuromuscular disease specialists to review emerging therapeutic data.
This presentation could influence clinical decision-making for older ambulatory Duchenne patients, a group currently facing limited treatment options. If the data proves favorable, it may expand the eligible population for gene therapy and potentially alter care standards. Families and physicians following these developments may gain new hope, though long-term effects and access costs remain open questions. The findings could also shape future trial designs and regulatory discussions across the rare disease community.